id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2012-0003,FDA,FDA-2022-E-2012,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-28T04:00:00Z,2022,9,2022-09-28T04:00:00Z,,2022-09-28T20:29:19Z,,0,0,090000648537ac35
FDA-2022-E-2012-0001,FDA,FDA-2022-E-2012,Letter from U S Patent and Trademark Office,Other,Letter(s),2022-08-25T04:00:00Z,2022,8,2022-08-25T04:00:00Z,,2022-08-25T14:01:30Z,,0,0,0900006485273903
FDA-2022-E-2012-0002,FDA,FDA-2022-E-2012,"Patent Term Extension Application for LYBALVI® Patent No 10,300,054",Other,Application,2022-08-25T04:00:00Z,2022,8,2022-08-25T04:00:00Z,,2022-08-25T14:04:42Z,,0,0,0900006485273baa